The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.

@article{Tsuprykov2016TheDP,
  title={The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.},
  author={Oleg Tsuprykov and Ryotaro Ando and Christoph Reichetzeder and Karoline von Websky and Viktoriia Antonenko and Yuliya Sharkovska and Lyubov Chaykovska and Jan Rahnenf{\"u}hrer and Ahmed Abdallah Hasan and Harald Tammen and Markus L. Alter and Thomas F. Klein and Shigeharu Ueda and Sho-Ichi Yamagishi and Shoji Okuda and Berthold Hocher},
  journal={Kidney international},
  year={2016},
  volume={89 5},
  pages={
          1049-1061
        }
}
Dipeptidyl peptidase (DPP)-4 inhibitors delay chronic kidney disease (CKD) progression in experimental diabetic nephropathy in a glucose-independent manner. Here we compared the effects of the DPP-4 inhibitor linagliptin versus telmisartan in preventing CKD progression in non-diabetic rats with 5/6 nephrectomy. Animals were allocated to 1 of 4 groups: sham operated plus placebo; 5/6 nephrectomy plus placebo; 5/6 nephrectomy plus linagliptin; and 5/6 nephrectomy plus telmisartan. Interstitial… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 53 REFERENCES

A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing

R R Core Team
  • 2015

Endothelin-1 Overexpression Improves Renal Function in eNOS Knockout Mice.

  • Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  • 2015
VIEW 1 EXCERPT